On May 17, Ricoh announced that it agreed to acquire a majority stake in a Baltimore, MD, biotech company that develops drug discovery products and services. Ricoh said that with its new subsidiary, Elixirgen Scientific, the company plans to grow its emerging biomedical operations into a ¥20 billion ($186 million) business by 2025. In 2019,
